| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
985.33(B) |
| Last
Volume: |
3,428,279 |
Avg
Vol: |
3,385,097 |
| 52
Week Range: |
$625.65 - $1022.87 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 19.5 |
| Insider 3/6 Months : 20.1 |
|
| Guru Rank Number : 412 |
| Guru Rank Value : 5.2 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
6,987 |
6,987 |
6,987 |
| Total Buy Value |
$0 |
$4,537,301 |
$4,537,301 |
$4,537,301 |
| Total People Bought |
0 |
8 |
8 |
8 |
| Total Buy Transactions |
0 |
8 |
8 |
8 |
| Total Shares Sold |
2,866,787 |
3,149,037 |
4,031,287 |
6,901,096 |
| Total Sell Value |
$2,147,483,647 |
$2,147,483,647 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
2 |
3 |
4 |
5 |
| Total Sell Transactions |
25 |
28 |
39 |
81 |
| End Date |
2025-08-22 |
2025-05-21 |
2024-11-20 |
2023-11-21 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Fyrwald J Erik |
Director |
– • – |
2025-11-17 |
4 |
A |
$1,021.70 |
$229,916 |
D/D |
225 |
74,989 |
|
- |
|
| Kaelin William G Jr |
Director |
– • – |
2025-11-17 |
4 |
A |
$1,021.70 |
$220,000 |
D/D |
215 |
21,837 |
|
- |
|
| Baicker Katherine |
Director |
– • – |
2025-11-17 |
4 |
A |
$1,021.70 |
$220,000 |
D/D |
215 |
23,503 |
|
- |
|
| Lilly Endowment Inc |
|
– – • |
2025-11-17 |
4 |
S |
$1,030.45 |
$10,189,269 |
D/D |
(9,886) |
92,872,191 |
|
-1% |
|
| Hedley Mary Lynne |
Director |
– • – |
2025-11-17 |
4 |
A |
$1,021.70 |
$229,916 |
D/D |
225 |
2,241 |
|
- |
|
| Johnson Kimberly H |
Director |
– • – |
2025-11-17 |
4 |
A |
$1,021.70 |
$220,000 |
D/D |
215 |
3,265 |
|
- |
|
| Jackson Jamere |
Director |
– • – |
2025-11-17 |
4 |
A |
$1,021.70 |
$220,000 |
D/D |
215 |
9,635 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2025-11-17 |
4 |
A |
$1,021.70 |
$234,833 |
D/D |
230 |
16,704 |
|
- |
|
| Greene Gabrielle E |
Director |
– • – |
2025-11-17 |
4 |
A |
$1,021.70 |
$224,958 |
D/D |
220 |
2,948 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2025-11-17 |
4 |
A |
$1,021.70 |
$231,749 |
D/D |
227 |
55,379 |
|
- |
|
| Moeller Jon R |
Director |
– • – |
2025-11-17 |
4 |
A |
$1,021.70 |
$238,333 |
D/D |
233 |
304 |
|
- |
|
| Lilly Endowment Inc |
|
– – • |
2025-11-14 |
4 |
S |
$1,030.31 |
$2,147,483,647 |
D/D |
(178,295) |
92,882,077 |
|
-0% |
|
| Lilly Endowment Inc |
|
– – • |
2025-11-13 |
4 |
S |
$1,030.21 |
$48,016,098 |
D/D |
(46,606) |
93,060,372 |
|
-1% |
|
| Zakrowski Donald A |
SVP, Finance, & CAO |
• – – |
2025-11-13 |
4 |
AS |
$1,010.50 |
$1,010,500 |
D/D |
(1,000) |
2,840 |
|
0% |
|
| Lilly Endowment Inc |
|
– – • |
2025-11-12 |
4 |
S |
$1,001.93 |
$308,411,204 |
D/D |
(305,000) |
93,106,978 |
|
-1% |
|
| Lilly Endowment Inc |
|
– – • |
2025-11-11 |
4 |
S |
$972.27 |
$279,347,680 |
D/D |
(283,131) |
93,411,978 |
|
-4% |
|
| Skovronsky Daniel |
EVP, CS&PO & Pres. LRL |
• – – |
2025-11-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
179 |
137,481 |
|
- |
|
| Ricks David A |
President, Chair, and CEO |
• • – |
2025-11-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
24,750 |
515,166 |
|
- |
|
| Lilly Endowment Inc |
|
– – • |
2025-11-10 |
4 |
S |
$972.17 |
$16,405,396 |
D/D |
(16,869) |
93,695,109 |
|
-7% |
|
| Brown Adrienne S |
EVP, President LLY ImmOfficer |
• – – |
2025-11-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,725 |
|
11% |
|
| Lilly Endowment Inc |
|
– – • |
2025-11-05 |
4 |
S |
$947.63 |
$38,473,442 |
D/D |
(40,432) |
93,711,978 |
|
-11% |
|
| Lilly Endowment Inc |
|
– – • |
2025-11-05 |
4 |
S |
$911.01 |
$167,092,104 |
D/D |
(179,042) |
93,752,410 |
|
-11% |
|
| Lilly Endowment Inc |
|
– – • |
2025-11-04 |
4 |
S |
$910.72 |
$479,038 |
D/D |
(526) |
93,931,452 |
|
-14% |
|
| Lilly Endowment Inc |
|
– – • |
2025-11-03 |
4 |
S |
$877.40 |
$266,648,921 |
D/D |
(300,000) |
93,931,978 |
|
-15% |
|
| Lilly Endowment Inc |
|
– – • |
2025-10-31 |
4 |
S |
$862.63 |
$260,165,031 |
D/D |
(301,342) |
94,231,978 |
|
-19% |
|
1470 Records found
|
|
Page 1 of 59 |
|
|
8.35 (0.82%) 
